Introduction {#S0001}
============

Chronic rhinosinusitis (CRS) is one of the most common diseases encountered by otolaryngologists and is estimated to affect 5--12% of the global population and 2--8% of Chinese people.[@CIT0001],[@CIT0002] At present, CRS is diagnosed based on the presence of the symptoms of nasal obstruction/congestion, facial pain/pressure, anterior/posterior discharge and/or olfactory loss for a duration greater than 12 weeks,[@CIT0003] which are persistent although﻿ not fatal, but result in negative influences on quality of life (QoL)[@CIT0004]

Despite the extensive studies on CRS, many uncertainties remain regarding its optimal treatment. Endoscopic sinus surgery (ESS) has been proven to be an effective method for improvement of QoL in patients with CRS.[@CIT0005],[@CIT0006] However, treatment for CRS with ESS can cause perioperative complications, such as cerebrospinal fluid (CSF) leak, orbital complications, sinonasal adhesions, infection, anxiety and bleeding[@CIT0007] The use of nasal fillings such as Merocel after ESS can cause serious pain and sleeplessness in patients, and removing the stuffing tends to cause further pain and bleeding, all of which affect patients' perioperative QoL.

Enhanced recovery after surgery (ERAS) is a series of optimized protocols adopted in the perioperative phase to reduce medical costs, shorten hospital stay, prevent perioperative complications and improve QoL. ERAS was pioneered by Kehlet[@CIT0008] and has been extended in many disciplines, for instance in the field of otolaryngology, such as head and neck oncological surgery.[@CIT0009]--[@CIT0012] In our previous study, the application of ERAS in ESS improved postoperative pain and sleep, while reducing hospital costs and length of hospital stay,[@CIT0013] which may be beneficial in improving the patients\' QoL. Therefore, the aim of this study was to assess the improvement in QoL in the perioperative period in ESS by the application of ERAS, using the Chinese version of the 22-item Sinonasal Outcomes Test (SNOT-22).

Materials and methods {#S0002}
=====================

Subjects {#S0002-S2001}
--------

From January 2018 to May 2018, patients diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP) and undergoing ESS in the Department of Otolaryngology at The Third Affiliated Hospital of Sun Yat-sen University were selected. Participants who met the inclusion criteria, and were not excluded based on the exclusion criteria, were randomly into an ERAS group and a control group for this prospective controlled clinical trial. This study was approved by the Ethics Committee of the hospital (number \[2018\]02-011-01) and was conducted in accordance with the Declaration of Helsinki. Informed consent forms were obtained from all participants, and the data on the SNOT-22 scores will be available from the web of the Chinese Clinical Trial Registry (number ChiCTR1800015791).

Inclusion criteria {#S0002-S2002}
------------------

Patients with CRSwNP confirmed by endoscopy, imaging and pathology according to the European Position Paper on Rhinosinusitis and Nasal Polyps 2012 (EPOS2012),[@CIT0003] without improvement of symptoms following conservative treatment, and patients ﻿diagnosed with sinusitis of full house, who underwent the same type of ESS by the same surgeon, were included in the study.

Exclusion criteria {#S0002-S2003}
------------------

Patients were excluded if they had chronic diseases including hypertension, tuberculosis, heart disease and asthma, or psychological disorders, and were unsuitable for surgery; or diseases such as Samter\'s triad, cystic fibrosis, primary ciliary dyskinesia, fungal sinusitis, systemic vasculitis, granulomatous disease and immunodeficiency. Patients who had undergone previous sinus surgery, ESS with septoplasty or turbinate surgery, or other surgery such as a modified Lothrop (DRAF-III) procedure were also excluded.

In addition, patients were excluded if the required data were not completely collected or the treatment failed to progress during the study.

Protocol for ERAS group {#S0002-S2004}
-----------------------

Patients followed the ERAS protocol during their hospital stay, as described previously.[@CIT0013] During the perioperative period, information on ERAS and a non-steroidal anti-inflammatory drug (NSAID) were given to patients. Patients fasted for 8 hours from solids and 2 hours from fluids, and consumed a carbohydrate drink 2 hours before surgery. In the intraoperative period, short-acting sedatives and short-acting opioid analgesics were given, and the body temperature and fluid volume were monitored during surgery. Topical tetracaine anesthesia and local lidocaine infiltration anesthesia were applied to the nasal mucosa, and degradable hemostatic material was used for nasal packing. In the postoperative period, patients were encouraged to undertake out-of-bed activities, and to consume food and drink according to their recovery condition after 2 hours. NSAIDs were given twice a day on postoperative day 1 (POD1) and POD2 ([Table 1](#T0001){ref-type="table"}).Table 1Implementation programs of the ERAS group and control group in the perioperative periodERAS protocolsControl groupPreoperative phaseEducationERAS education was explainedCommon processingFasting for food and liquidNo food for 8 hours and no fluid for 2 hours before surgery8 hours before surgeryCarbohydrate2 hours before surgeryNonePain managementNSAID was given the night before surgeryCommon processingIntraoperative phaseAnalgesia managementShort-acting sedative and opioid analgesicsLong-acting sedative and opioid analgesicsPain managementTopical tetracaine and lidocaine were administeredCommon processingTemperature monitoringAvoidance of hypothermiaCommon processingFluid managementFluid and saline infusions were reducedCommon processingPostoperative phasePain managementNSAID was given twice for 24 hours after surgeryCommon processingEarly eating and drinking2 hours after surgery6 hours after surgeryEarly out-of-bed activity2 hours after surgery6 hours after surgery[^2]

Protocol for control group {#S0002-S2005}
--------------------------

Patients followed a traditional protocol during their hospital stay, as described previously[@CIT0013] During the perioperative period, traditional perioperative information was given to patients, but without NSAIDs. Patients fasted for 8 hours from solids and fluids before surgery. In the intraoperative period, long-acting sedatives and long-acting opioid analgesics were given, and the body temperature and fluid volume were monitored as common procedures. No topical tetracaine anesthesia or local lidocaine infiltration anesthesia was applied to the nasal mucosa, and non-degradable hemostatic material was used for nasal packing according to the traditional protocol. In the postoperative period, patients were encouraged to perform out-of-bed activities, and to take food and drink according to their recovery condition after 6 hours. NSAIDs were given as needed ([Table 1](#T0001){ref-type="table"}).

Chinese version of SNOT-22 assessment {#S0002-S2006}
-------------------------------------

The SNOT-22 is a validated, disease-specific QoL questionnaire used for CRS[@CIT0014] This questionnaire provides a symptom score for 22 parameters (range 0--5) relating to sinonasal function, with the minimum score being 0 points and the maximum score being 110. It can be categorized into five domains: domains 1, 2 and 3 (rhinological symptoms, extranasal rhinological symptoms and ear/facial symptoms, respectively) relate to sinus-specific symptoms; and domains 4 and 5 (psychological dysfunction and sleep dysfunction, respectively) cover general health-related QoL. In this trial, we used the Chinese version of SNOT-22.[@CIT0015] The higher the score, the worse the QoL.

Data collection {#S0002-S2007}
---------------

The SNOT-22 was explained to patients, usually 1 or 2 days before surgery. The questionnaire was completed by the patients to determine their preoperative baseline health status. The SNOT-22 was repeated and collected by the same researcher on POD1, 3 and 6 in the hospital. Postoperative complications, such as nausea/emesis, hemorrhage, aspiration and dizziness, were also recorded.

Statistical analysis {#S0002-S2008}
--------------------

All statistical analyses were performed using the IBM-SPSS version 20 software program (IBM Corp., Armonk, NY, USA). Measurement data (such as scores on Lund--Mackay, Lund--Kennedy and SNOT-22) are presented as mean ± SD, and an two-tailed independent samples *t*-test was used for comparison between the two groups. Enumeration data (such as postoperative complications) are presented as N (%), and Fisher's exact test or the chi-squared﻿ test was used. A value of *P*\<0.05 was considered to be statistically significant.

Results {#S0003}
=======

Case series {#S0003-S2001}
-----------

In total, 74 patients met the inclusion criteria and were included in the study. Patients were divided at random into the ERAS group (n=36) and control group (n=38). The ERAS group consisted of 26 males and 10 females with an average age of 37.9 years, while the control group consisted of 29 males and 9 females with an average age of 39.4 years (*t*=0.677, *P*\>0.05). All of the patients successfully completed the study and were followed up.

The Lund--Mackay staging scores for the ERAS group and the control group were 18.28±3.77 and 18.89±2.62 (*t*=0.8126, *P*\>0.05), and the Lund--Kennedy staging scores were 5.39±1.57 and 5.16±1.44 (*t*=0.961, *P*\>0.05) respectively.

SNOT-22 assessment {#S0003-S2002}
------------------

The preoperative global SNOT-22 scores, as shown in [Table 2](#T0002){ref-type="table"}, indicating the baseline health status, were 39.89±4.86 in the ERAS group and 40.52±3.61 in the control group (*t*=0.643, *P*=0.522). On POD1, the global SNOT-22 scores increased significantly to 51.77±5.59 and 62.02±3.86 (*t*=9.218, *P*\<0.01), and on POD3 they increased to 48.22±6.22 and 51.11±5.14 (*t*=2.179, *P*\<0.05), respectively, in the ERAS and control groups. On POD6, the scores recovered to 39.39±4.73 and 40.13±3.31, which were lower than but not statistically significantly different from baseline (*t*=0.786, *P*=0.434). Table 2SNOT-22 assessment of the ERAS group and control group in the perioperative periodPreoperativePOD1\*POD3POD6ERASControlERASControlERASControlERASControl**Rhinological symptoms**14.14±2.8714.16±1.9216.67±2.3320.34±1.1015.52±2.2516.15±1.4213.70±1.7713.82±1.23**Extranasal rhinological symptoms**6.03±2.386.29±1.498.03±2.319.10±2.207.56±2.308.03±2.016.11±1.896.34±1.56**Ear/facial symptoms**5.14±2.215.08±2.027.42±2.138.63±2.626.67±2.396.92±2.564.92±1.894.92±2.16**Psychological dysfunction**3.16±1.363.18±1.185.56±1.706.81±1.045.52±2.135.84±2.304.14±1.664.32±1.10**Sleep dysfunction**11.41±3.0611.81±2.9414.11±3.1617.13±1.5412.94±3.0414.16±2.4410.53±2.0510.73±2.49**SNOT-22 total score**39.89±4.8640.52±3.6151.77±5.5962.02±3.8648.22±6.2251.11±5.1439.39±4.7340.13±3.31[^3]

There were statistically significant improvements across all subdomains of the SNOT-22 questionnaire for patients in the both the ERAS group and control group on POD1 (all *P*\<0.05). Among the subdomains, the rhinological and sleep components appeared to account for a large improvement in QoL. The mean rhinological subdomain score for the ERAS group was 14.14 at baseline and 16.67 on POD1, while the mean rhinological subdomain score for the control group was 14.16 at baseline and 20.34 on POD1 (*t*=8.756, *P*\<0.01). The mean sleep subdomain score for the ERAS group was 11.41 at baseline and 14.11 on POD1, while the mean sleep subdomain score for the control group was 11.81 at baseline and 17.13 on POD1 (*t*=5.266, *P*\<0.01).

Postoperative complications {#S0003-S2003}
---------------------------

Four patients in the ERAS group and three patients in the control group experienced nausea/emesis 2 hours after surgery (*χ*^2^=0.223, *P*\>0.05), and they were not encouraged to engage in early out-of-bed activities or early eating and drinking. However, the symptoms were soon alleviated with conservative treatment. No other complications, such as hemorrhage, aspiration or dizziness, were observed.

Discussion {#S0004}
==========

Based on the collected data, in the ERAS protocol for ESS, pain management with effective pain control based on preventive and multimodal analgesia enabled the patients to consume food and fluids and engage in out-of-bed activities in the early stages. We also found that ERAS in ESS can improve postoperative pain, sleep, comfort levels and postoperative systemic inflammatory reactions, while reducing hospital charges and length of hospital stay[@CIT0013] All of these factors contribute to the improvement of QoL in patients with CRS[@CIT0013]

CRS-associated QoL research has gained significant importance and many disease-specific QoL instruments have been used in the evaluation and treatment of ESS.[@CIT0016]--[@CIT0018] Although we have previously compared the differences between the two groups using the Self-rating Anxiety Scale (SAS), visual analog scale (VAS), Medical Outcomes Study Sleep Scale (MOS-SS) and Kolcaba General Comfort Questionnaire (GCQ),[@CIT0013] SNOT-22 has emerged as a commonly used CRS-specific QoL metric and has been evaluated as the primary outcome in prospective studies.[@CIT0019],[@CIT0020]

Baseline SNOT-22 scores can be used to predict treatment selection for CRS, and the baseline SNOT-22 scores can be used to inform patients about their expected QoL outcomes after ESS[@CIT0021] Also, studies have shown that patients with preoperative SNOT-22 scores between﻿ 10 and 19 reported a worsening of their QoL 14 months after ESS compared with patients with preoperative SNOT-22 scores greater than 30.[@CIT0022],[@CIT0023] A meta-analysis of SNOT-22 outcomes after ESS showed a statistically significant change in mean SNOT-22 scores ranging from 12.7 to 44.8 between baseline and postoperative time-points, with an average follow-up of 10.6 months[@CIT0024] However, all those studies concentrated on the improvement of QoL from baseline to a long time after ESS using SNOT-22. Few reports, especially random controlled clinical trials, have been published on the perioperative QoL in ESS using SNOT-22 scores.

In this study, SNOT-22 scores correlated with the perioperative QoL. On POD1, the global SNOT-22 scores in the ERAS and control groups increased significantly to 51.77±5.59 and 62.02±3.86, respectively (*t*=9.218, *P*\<0.01), and on POD3 they increased to 48.22±6.22 and 51.11±5.14 (*t*=2.179, *P*\<0.05), respectively. However, the scores recovered to 39.39±4.73 and 40.13±3.31, respectively, on POD6, which were lower than but not statistically significant different from the baseline (*t*=0.786, *P*=0.434). The rhinological and sleep components appeared to account for a large improvement in SNOT-22. All of these results indicated that patients with CRSwNP who underwent ESS with the application of ERAS had an improved perioperative QoL compared with patients under the traditional protocol.

A VAS of each index (nasal obstruction, sleep disturbance and head/facial pain) at 3 was set as a discharge criterion for ERAS in septoplasty in our previous study[@CIT0025] However, ESS for CRS is day surgery in the USA and other developed countries. Patients require several days of hospitalization for ESS in China because of bed occupancy. Usually, patients are discharged after the first postoperative endoscopic cleaning of the nasal cavities. Here, we also used SNOT-22 as a patient-reported outcome in discharge criteria in ESS. As shown in [Table 2](#T0002){ref-type="table"}, the scores on the SNOT-22 decreased significantly on POD3 in the ERAS group compared to the control group (*t*=2.179, *P*\<0.05), and the scores recovered on POD6, which were lower, but not statistically significant, compared to the baseline (*t*=0.786, *P*=0.434). All of these findings indicated that the QoL was improved with discharge around POD3 for patients undergoing ESS.

It must not be forgotten that medical treatment, such as ERAS, carries a risk of complications. Major complications of ESS include CSF leak and orbital complications including orbital ecchymosis, diplopia or reduction of visual acuity, and significant intraoperative or immediate postoperative hemorrhage. Minor complications include adhesions, infection, bleeding and postoperative pain[@CIT0026] However, none of these complications was observed in either group in this study, and the ERAS group did not experience increased complications, such as nausea/emesis, hemorrhage, aspiration and dizziness, compared with the control group.

There are several limitations to this study. One limitation is that this investigation represents the experience of a single institution with a relatively small series. It calls for a multicenter randomized controlled study with a large sample to gain a more complete picture of QoL in ESS under ERAS. Another limitation is that the SNOT-22 questionnaire scores only reflect a subjective assessment of patients' QoL. Objective evaluations such as C-reactive protein and interleukin-6 may be used in future investigations to capture aspects of QoL not evaluated by the questionnaire.[@CIT0027],[@CIT0028]

Conclusion {#S0005}
==========

This study clearly demonstrated that ERAS could improve perioperative QoL in patients with CRSwNP undergoing ESS, with significant improvements in scores on rhinological symptoms, extranasal rhinological symptoms, ear/facial symptoms, psychological dysfunction and sleep dysfunction.
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